Mungunkhuyag, Uranchimeg
Loading...
Товч нэр
Mungunkhuyag, Uranchimeg
Бүтэн нэр
Mungunkhuyag Uranchimeg
Латин нэр
Mungunkhuyag Uranchimeg
Албан тушаал
Судлаач
ORCID
Now showing 1 - 2 of 2
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Changes in mental health following COVID-19 infection: Results of a prospective cohort study in Mongolia(Mongolian National University of Medical Sciences, 2026-03-30); ; Yelik MadiObjective: COVID-19 has been associated with persistent neuropsychiatric complications, yet prospective evidence from low- and middle-income countries remains limited. This study evaluated 12-month longitudinal changes in depression, anxiety, insomnia, and post-traumatic stress disorder (PTSD) among hospitalized patients with COVID-19 compared with non-COVID-19 controls in Mongolia. Methods: This prospective cohort study included 459 adults (326 COVID-19 cases and 133 controls) recruited from hospitals affiliated with the Mongolian National University of Medical Sciences between 2021 and 2023. Participants without baseline mental disorders were assessed at 7–14 days, 3 months, and 12 months using the PHQ-9, GAD-7, ISI, and PCL-5. Data were analyzed using X² tests, independent t-tests, and relative risk (RR) estimates, with statistical significance defined as p < 0.05. Results: The mean age of participants was 46.3 ± 13.8 years, and 58.4% were female. At 12 months, depression (37.3% vs. 16.9%; RR = 2.22, 95% CI: 1.28–3.83; p = 0.003) and anxiety (28.0% vs. 11.2%; RR = 2.49, 95% CI: 1.25–4.96; p = 0.006) remained significantly more common in the COVID-19 group than in controls. Insomnia decreased over time (33.3% vs. 49.4%; RR = 0.67; p = 0.037), whereas PTSD prevalence remained low in both groups (<3%, p > 0.05). Female participants and those aged 40–59 years showed a higher risk of adverse mental health outcomes. Conclusions: COVID-19 infection was associated with a significantly increased long-term risk of depression and anxiety up to 12 months after infection. These findings support routine mental health screening and sustained psychological follow-up as part of post-COVID care and provide evidence to inform long-term mental health policy in Mongolia. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, DAST-28 severity and injection-related harm risks among people using psychoactive substances in psychiatric and correctional settings in Mongolia: a multicenter cross-sectional study(Elsevier BV, 2026-12); ; ; ; Mandakh, MunkhnaranINTRODUCTION: Evidence on drug-related problem severity and injection-related harm among people using psychoactive substances in Mongolia is limited, particularly in institutional settings. We examined DAST-28 scores, internal consistency, and behavioral correlates in psychiatric and correctional settings. METHODS: This multicenter cross-sectional study included 181 participants recruited from the National Center for Mental Health and correctional facilities. The continuous DAST-28 total score was the primary outcome. Internal consistency was evaluated from 28 item responses. A clinically specified seven-covariate linear model with HC3 heteroskedasticity-robust standard errors was primary; ordinal and study-defined DAST-28 ≥ 12 models were supportive analyses. RESULTS: DAST-28 scores were available for 179 participants (median 11.0, interquartile range 6.0-16.0). Among 170 participants with complete item responses, Cronbach's alpha was 0.882 (95% bootstrap confidence interval 0.854-0.902). In the primary model, correctional setting was associated with a 1.82-point lower score (95% CI -3.36 to -0.28), whereas each additional year of use (B = 0.27, 95% CI 0.08-0.45), polysubstance use (B = 2.64, 95% CI 0.79-4.50), and any syringe use (B = 4.43, 95% CI 2.58-6.28) were associated with higher scores. Ordinal and threshold analyses were concordant; variance inflation factors ranged from 1.05 to 1.59. CONCLUSIONS: Greater DAST-28 scores were associated with polysubstance use, syringe use, and longer use duration in these institutional samples. The findings may inform comprehensive assessment and harm-reduction linkage but do not establish a diagnostic cutoff, causal relationship, intervention effectiveness, or population prevalence.